E
GYRE icon

Ergoteles’s Gyre Therapeutics GYRE Stock Holding History

Ergoteles’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,354
Closed -$10.4K – 1215
2023
Q1 		$10.4K Buy
+3,354
New +$12.7K ﹤0.01% 1172
2021
Q4 		– Sell
-14,028
Closed -$432K – 1386
2021
Q3 		$432K Sell
14,028
-439
-3% -$14.4K 0.02% 640
2021
Q2 		$470K Buy
+14,467
New +$496K 0.01% 843

Other funds holding GYRE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Ergoteles's GYRE Position: Q2 2023 in Review

Ergoteles sold out of Gyre Therapeutics (GYRE) in Q2 2023, closing a stake of 3,354 shares — an estimated $10.4K sold.

Ergoteles first reported a position in GYRE in Q2 2021 and held it in 3 quarters. The position peaked at $470K in Q2 2021. 28 funds tracked by Wall St. Rank hold GYRE as of Q2 2023.

  • Ergoteles reported no remaining Gyre Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 3,354 Gyre Therapeutics shares in Q2 2023, an estimated $10.4K.
  • Ergoteles first reported a position in Gyre Therapeutics in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Gyre Therapeutics position peaked at $470K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.